Lotus Pharmaceutical Co., Ltd.

NT$166.00As of Sun 8 Nov 2026, 12:00 UTC
TWSE:1795Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 12.32%
Div yield 1.53%
ROE 16.86%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.73
PE TTM 11.67
TSR TTM (42.33%)
Mkt cap NT$44.77B
ROIC 7.47%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$199
19.67%
63.41%
Hold 9|5|1|8|10
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
2.05
2.09
2.15
2.26
36.15%
24.31%
21.31%
14.15%
RevenueNT$B
4.374
4.381
4.472
4.706
5.32%
1.93%
4.16%
12.37%
Peers (US$1.352B)
Cap (US$)
PE
673.7M
22.18x
Capital
TTM
5Y
10Y
Leveragex
0.570
(0.194)
(0.137)
EBIT/Intx
0.985
0.371
0.345
Own earn%
158.70
30.19
24.88
Sh yield%
20.65
25.65
27.94
Owners
Insiders/Inst%
9.90
36.84
Short interest%
4.78
SBC / revenue%
1.99
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
7
Op margin range%
21–30
$1 testx
—
Incr. ROIC%
12